StreetAlpha.app
Home › Stocks › GLUE

Monte Rosa Therapeutics, Inc. (GLUE)

Healthcare
$9.07
▼ −0.98%
LAST CLOSE · NOV 17

Monte Rosa Therapeutics develops small molecule drugs that break down proteins tied to immune disorders and cancers. It last closed at $9.07 on Nov 17, down 0.98% on the day. The average 12-month price target from 5 analysts is $24.80 (+173.4% from the last close), with a high of $28.00 and a low of $19.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).

AI Auto Pilots
Is GLUE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$70.3M
−61.3% vs a year ago
Net income
−$130.9M
−725.2% vs a year ago
Free cash flow
−$174.4M
−248.0% margin
Operating margin
−214.5%
−$150.8M operating income
Valuation
Market cap
$775.0M
85.5M shares
P/E
–
Price to sales
11.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$45.2M
At Sep 30
Shareholder equity
$496.2M
Shares outstanding
85.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $75.6M$75.6MFY2024FY2025: $123.7M$123.7MFY2025

From GLUE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on GLUE in the past 90 days
Average 12-month target
$24.80
▲ 173.4% upside

Based on 5 analysts who set a price target on GLUE in the past 90 days. The average target is $24.80, with a high of $28.00 and a low of $19.00, compared with the last close of $9.07.

Low $19.00Avg $24.80High $28.00
Blue marker: last close $9.07
Highest target$28.00
Average target$24.80
Lowest target$19.00
Latest rating changes
Wells FargoTarget lowered
Nov 6Buy$27 → $25
UBSAssumed coverage
Oct 12Buy$19
HC Wainwright & Co.Reiterated
Oct 5Buy$25
HC Wainwright & Co.Initiated
Oct 1Buy$25
WedbushReiterated
Sep 9Buy$27
DateFirmActionRatingPrice target
Nov 6Wells FargoTarget loweredBuy$27 → $25
Oct 12UBSAssumed coverageBuy$19
Oct 5HC Wainwright & Co.ReiteratedBuy$25
Oct 1HC Wainwright & Co.InitiatedBuy$25
Sep 9WedbushReiteratedBuy$27
Loading…

Technical Analysis

GLUE · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 15% below its 20 day and 22% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot at $9.06, and the nearest resistance the Pivot R1 at $9.29.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.7%/day
Key levels
$25.7752 week high+184.1%
$16.63200 day average+83.4%
$14.98100 day average+65.2%
$11.1050 day average+22.4%
$10.85Swing high (Nov 10)+19.6%
$10.3920 day average+14.6%
$9.29Pivot R1+2.4%
$9.07Last close
$9.06Pivot−0.1%
$8.84Pivot S1−2.5%
$8.8352 week low−2.6%
Indicators
RSI (14)30.92Weak, oversold below 30Neutral
MACD-0.51Below its signal lineBearish
Stochastic12.8Near the bottom of its rangeOversold
ADX (14)27.3Trending down
Williams %R-89.9Oversold below −80, overbought above −20Oversold
CCI (20)-192.2Oversold below −100, overbought above 100Oversold
Rate of change−12.9%Change over 10 sessionsBearish
ATR (14)$0.61Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GLUE

What happened before

See how GLUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GLUE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GLUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GLUE in the last 90 days.

Loading…

See today’s whale options flow across the market →

GLUE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●97 buying vs 104 selling
  • ▼Held by funds -1.1 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding191195−2.1%
In funds' top 1046−33.3%
Held by funds108.1%109.2%−1.1 pts
New / increased37 / 6029 / 82−12.6%
Reduced / sold out64 / 4059 / 23+26.8%
Put/call ratio0.030.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GLUE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GLUE is in one of them and how their past GLUE trades turned out.

GLUE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GLUE in an article yet. Here's the latest on the wider market.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company based in Boston, Massachusetts. It develops small molecule drugs called molecular glue degraders, which use the body's natural protein disposal system to break down proteins tied to disease. Its candidates are in clinical trials for immune conditions, inflammatory diseases, and prostate cancer, and it is developing programs for other cancers. Its main partner is Novartis, which has licensed one of its immune disease programs.

Headquarters
Boston, MA